Brief Article
Copyright ©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Oct 28, 2012; 18(40): 5779-5788
Published online Oct 28, 2012. doi: 10.3748/wjg.v18.i40.5779
Table 2 Characteristics of cohort studies (n = 3) included in meta-analysis regarding use of bisphosphonates and risk of cancer
Ref.CountryCohort formation (population)Study periodMean F/U duration, yr (range)Age, yr (mean±SD)Sex ratio (reference group)Type of cancerType of drug (reference group)Risk estimateAdjustmentNo. of cancer development/ no. of study population
No. of total cohort
Bisphosphonate userReference group
Abrahamsen et al[10]DenmarkPatients with fracture who had prescription for oral bisphosphonate (national registers)E:1995-2005; F/U: -20052.8 (NA)74.3 ± 8.8M: 11; F: 89Esophageal cancer, gastric cancerAny bisphosphonate use (no bisphosphonate use)Esophageal or gastric cancer 0.78 (0.49-1.26); esophageal cancer 0.35 (0.14-0.85); gastric cancer 1.23 (0.68-2.22)Age, sex, fracture type, Charlson index, number of concomitant medication, time to eventNA/13 678NA/27 35641 034
Solomon et al[11]United StatesPatients who had prescription for oral bisphosphonate (health care utilization records of medicare beneficiaries)NANA (NA)NANAEsophageal cancerAny bisphosphonate use (other osteoporosis medications use)Esophageal cancer 0.55 (0.06-4.72)NAIncidence rate 26.7/100 000Incidence rate 48.4/100 000NA
Cardwell et al[7]United KingdomPatients receiving prescription for oral bisphosphonate (GPRD)E:1996-2006; F/U: -20084.5 (0.5-12.9)70.0 ± 11.4M: 19; F: 81Esophageal cancer, gastric cancerAny bisphosphonate use (regardless of bisphosphonate use)Gastric cancer 0.78 (0.50-1.23); esophageal cancer 1.07 (0.77-1.49)Age, sex, general practice, BMI, cigarette smoking, alcohol intake, hormone therapy, NSAID use, Barrett's esophagus, GERD, H2 receptor antagonist use, proton pump inhibitor useEsophageal or gastric cancer 116/41 826 (gastric cancer 37/41 826; esophageal cancer 79/41 826)Esophageal or gastric cancer 115/41 826 (gastric cancer43/41 826; esophageal cancer 72/41 826)83 652